Ann: Presentation at AusBiotech Invest and Partnering 2018, page-5

it seems more to be the theory that Neuren is trying to capitalize the maximum of Trofinetide to steep to move decisively 2591. the facts of the last days suggest that Neuren is gradually passing the whole package, probably inclusive of FX, in exchange for money in the short and in the long run, but more importantly, by retaining the free use of all data generated by Acadia that will be the basis for a rapid advancement of NNZ-2591 in fact become the main goal of Neuren. there is money to progress in the clinical development that I remember was apparently suspended about ten years ago and in the hands of the military.
since nothing is random it is reasonably consistent to expect Acadia to continue to finance Neuren a steep, which will involve US ARMY and any third party as a biotech level, to establish an operational plan for 2591. If so, we will have a title that will build a strong positive trend that will give shareholders satisfaction over time; the conditions on the market, on the other hand, will have to respect the key point of 1.64 $ which enables the conversion of the options of the managers who are waiting to translate the conditions favorable to them of the stock plan already fully achieved by objectives. if the market is able to trade above this level then scenarios will be opened that are consistent with the potential value per share we aspire to.